Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.

@article{Pollack1997AbecarnilFT,
  title={Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.},
  author={Mark H. Pollack and John J. Worthington and Gisele Gus Manfro and Michael W Otto and Bonnie G Zucker},
  journal={The Journal of clinical psychiatry},
  year={1997},
  volume={58 Suppl 11},
  pages={19-23}
}
BACKGROUND The development of effective and well-tolerated anxiolytic agents is an area of critical clinical importance. Abecarnil, a beta carboline, is a partial benzodiazepine-receptor agonist that has demonstrated promise as an anxiolytic agent. In this study, we examine the efficacy, safety, and discontinuation-related effects of abecarnil, buspirone, and placebo in the acute and long-term treatment of patients who have generalized anxiety disorder. METHOD This is a double-blind, placebo… CONTINUE READING